Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
Funding Amount
Not stated
Deadline
September 25, 2028
687 days left
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Public colleges & universities
- Tribal organizations
- Tribal governments
- Small businesses
- State governments
- Public & Indian housing authorities
- County governments
- Nonprofits (501(c)(3))
Overview
Avant Garde/Avenir award for Investigators conducting high risk/high reward research on HIV and Substance Use (or Substance Use Disorders)
The National Institue on Drug Abuse (NIDA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research on pioneering research in HIV and Substance use/substance use disorder (SUD) research. The Avant-Garde Award Program is designed to support exceptionally creative scientists who propose cutting edge high risk and high reward and possibly transformative approaches to major challenges in biomedical and behavioral research on HIV in the context of substance use and/or SUDs. This Program includes supporting early stage investigators (ESI). Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the DP1 activity code. Investigators with expertise and insights into this area of substance use and HIV are encouraged to begin to consider applying for this new NOFO.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: FOR-DA-27-003
- Instrument: grant
Focus Areas & Funding Uses
Fields of Work
- HIV/AIDS
- Addiction recovery
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$6,300,000 total
Deadline
November 9, 2026
Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
National Institutes of Health
Amount
$1,000,000 total
Deadline
November 9, 2026
Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)
National Institutes of Health
Amount
$15,000,000 total
Deadline
November 10, 2026
Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
November 10, 2026
Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
National Institutes of Health
Amount
$29,000,000 total
Deadline
November 10, 2026
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$50,000 - $300,000
Deadline
November 10, 2026
Ready to apply for Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional). Now let's win it.